Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement … (NCT07558603) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
United States50 participantsStarted 2026-04-20
Plain-language summary
The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires/assessments, photography, skin imaging, and reported adverse reactions.
Who can participate
Age range45 Years – 65 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Post-menopausal women (25 on HRT, 25 non HRT all must be post-menopausal)
✓. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.
✓. Adult women aged 45-65 years.
✓. Fitzpatrick skin types I-VI.
✓. Current treatment with a stable dose of any GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least the last 3 months
✓. Must be willing to sign a photography release and ICF,and complete the entire course of the study.
✓. Subjects in good general health based on the investigator's judgment and medical history.
Exclusion criteria
✕. Non post-menopausal state.
✕. Any uncontrolled systemic disease.
✕. History of autoimmune connective tissue disease.
✕. Current use of immunosuppressive medication.
✕. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
✕. Active dermatitis or active infection in the proposed treatment area.
✕. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment.
✕. Microneedling treatments of the face and neck during the 1 month period before study treatment